Trials With ABT-199 Held Up; Patient Death on AbbVie Drug?
Backing up the European approval of Humira (adalimumab) with more data, Abbott spinout AbbVie for the first time offered long-term, patient-reported health outcomes data from the Phase III IMAgINE-1 trial in young people with Crohn's disease, along with favorable results of a caregiver survey.
Suite: 1100 | Atlanta, Georgia 30346, USA
Tel: +1 877.857.2477
Outside of the US
Tel. +44 203 684 1796
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter